FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like Merck, Orion Join Forces to Develop Novel Treatment for Prostate Cancer July 13, 2022 Biden Administration Misses Key Deadline, Likely Pushing Califf Nomination Vote into 2022 November 24, 2021 Developers Voice Concern Over Draft Guidance Closing Orphan Drug Loophole February 21, 2018
Biden Administration Misses Key Deadline, Likely Pushing Califf Nomination Vote into 2022 November 24, 2021